On 9 January 2020, orphan designation EU/3/19/2240 was granted by the European Commission to BIT Pharma GmbH, Austria, for nicardipine for the treatment of non-traumatic subarachnoid haemorrhage.
Treatment of non-traumatic subarachnoid haemorrhage
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.